The diagnostic and clinical benefits of genomic sequencing are being increasingly demonstrated across multiple rare genetic conditions. Despite the expanding clinical literature, there is a significant paucity of health economics evidence to inform the prioritization and implementation of genomic sequencing. This study aims to evaluate whether genomic sequencing for pediatric-onset mitochondrial disorders (MDs) is cost-effective and cost-beneficial relative to conventional care from an Australian healthcare system perspective. Two independent and complementary health economic modeling approaches were used. Approach 1 used a decision tree to model the costs and outcomes associated with genomic sequencing and conventional care. Approach 2 used a discrete-event simulation to incorporate heterogeneity in the condition and clinical practice. Deterministic and probabilistic sensitivity analyses were performed. Genomic sequencing was less costly and more effective compared with conventional care, saving AU$1997 (Approach 1) to AU$8823 (Approach 2) per child tested, while leading to an additional 11 (Approach 1) to 14 (Approach 2) definitive diagnoses per 100 children tested. The mean monetary value of the incremental benefits of genomic sequencing was estimated at AU$5890 (95% CI: AU$5730−$6046). Implementation of genomic sequencing for MDs in Australia could translate to an annual cost-saving of up to AU$0.7 million. Genomic sequencing is cost-saving relative to traditional investigative approaches, while enabling more diagnoses to be made in a timely manner, offering substantial personal benefits to children and their families. Our findings support the prioritization of genomic sequencing for children with MDs.
Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain. 2003;126:1905–12.
Tan J, Wagner M, Stenton SL, Strom TM, Wortmann SB, Prokisch H, et al. Lifetime risk of autosomal recessive mitochondrial disorders calculated from genetic databases. EBioMedicine. 2020;54:102730.
Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, et al. Mitochondrial diseases. Nat. Rev. Dis. Primers. 2016;2:16080.
Grier J, Hirano M, Karaa A, Shepard E, Thompson JLP. Diagnostic odyssey of patients with mitochondrial disease: results of a survey. Neurol. Genet. 2018;4:e230.
Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the mitochondrial medicine society. Genet. Med. 2015;17:689–701.
Wortmann SB, Mayr JA, Nuoffer JM, Prokisch H, Sperl W. A guideline for the diagnosis of pediatric mitochondrial disease: the value of muscle and skin biopsies in the genetics era. Neuropediatrics. 2017;48:309–14.
Wu Y, Al-Janabi H, Mallett A, Quinlan C, Scheffer IE, Howell KB, et al. Parental health spillover effects of paediatric rare genetic conditions. Qual. Life Res. 2020;29:2445–54.
Payne K, Gavan SP, Wright SJ, Thompson AJ. Cost-effectiveness analyses of genetic and genomic diagnostic tests. Nat. Rev. Genet. 2018;19:235–46.
Best S, Stark Z, Phillips P, Wu Y, Long JC, Taylor N, et al. Clinical genomic testing: what matters to key stakeholders? Eur. J. Hum. Genet. 2020;28:866–73.
Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom. Med. 2018;3:16.
Kohler JN, Turbitt E, Biesecker BB. Personal utility in genomic testing: a systematic literature review. Eur. J. Hum. Genet. 2017;25:662–8.
Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet. Med. 2018;20:1122–30.
Stenton SL, Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine. 2020;56:102784.
Goranitis I, Best S, Christodoulou J, Stark Z, Boughtwood T. The personal utility and uptake of genomic sequencing in pediatric and adult conditions: eliciting societal preferences with three discrete choice experiments. Genet. Med. 2020;22:1311–9.
Goranitis I, Best S, Stark Z, Boughtwood T, Christodoulou J. The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment. Genet. Med. 2021;23:155–62.
Morava E, van den Heuvel L, Hol F, de Vries MC, Hogeveen M, Rodenburg RJ, et al. Mitochondrial disease criteria: diagnostic applications in children. Neurology. 2006;67:1823–6.
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–7. Med. Decis. Mak. 2012;32:733–43.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405–24.
Medicare Australia. Medicare Benefits Schedule (MBS) Item Statistics Reports. 2008. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/FBE6CC5B217AC8DACA25859E0016F5A3/$File/July20_Complete%20MBS.pdf.
Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. Canberra, Australia: Australian Government, Department of Health and Ageing; 2008.
Small KA, Rosen HS. Applied welfare economics with discrete choice models. Econometrica: J. Econom. Soc. 1981;49:105–30.
Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87.
Australian Bureau of Statistics (ABS). National, state and territory population statistics. ABS; 2020. https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/mar-2020.
Yeung A, Tan NB, Tan TY, Stark Z, Brown N, Hunter MF. et al. A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients. Genet. Med.2020;22:1986–93.
Li C, Vandersluis S, Holubowich C, Ungar WJ, Goh ES, Boycott KM. et al. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies. Genet. Med.2021;23:451–60.
Brennan A, Akehurst R. Modelling in health economic evaluation. Pharmacoeconomics. 2000;17:445–59.
Marshall DA, Grazziotin LR, Regier DA, Wordsworth S, Buchanan J, Phillips K, et al. Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling. Value Health. 2020;23:566–73.
Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, et al. Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. Value Health. 2018;21:1033–42.
Regier DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions. Value Health. 2018;21:1043–7.
Belsey J, Chaihorsky L, Currie G, Goranitis I, Marshall D. Global data access for solving rare disease: a health economics value framework. World Economic Forum. 2020. http://www3.weforum.org/docs/WEF_Global_Data_Access_for_Solving_Rare_Disease_Report_2020.pdf.
Lehtonen JM, Auranen M, Darin N, Sofou K, Bindoff L, Hikmat O. et al. Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease. J. Inherit. Metab. Dis.2020;44:469–80.
Canadian Agency for Drugs Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies. Ottawa, Canada; CADTH; 2006.
National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London, UK; NICE; 2013.
Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee Canberra, Australia; PBAC; 2016.
Buchanan J, Wordsworth S. Evaluating the outcomes associated with genomic sequencing: a roadmap for future research. PharmacoEconomics Open. 2019;3:129–32.
De Civita M, Regier D, Alamgir AH, Anis AH, FitzGerald MJ, Marra CA. Evaluating health-related quality-of-life studies in paediatric populations. Pharmacoeconomics. 2005;23:659–85.
Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet. Med.2008;10:648–54.
Australian Genomics Health Alliance is funded by a National Health and Medical Research Council (NHMRC) grant (GNT: 1113531) and the Australian Government’s Medical Research Future Fund (MRFF), and a NHMRC research fellowship (GNT: 1102896). Philanthropic support from the Crane and Perkins families also funded this project. The research conducted at the Murdoch Children’s Research Institute was supported by the Victorian Government’s Operational Infrastructure Support Program. This work represents independent research and the views expressed are those of the authors and not necessarily those of the NHMRC or MRFF.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wu, Y., Balasubramaniam, S., Rius, R. et al. Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation. Eur J Hum Genet (2021). https://doi.org/10.1038/s41431-021-00916-8